In addition, key regulators of cellular bioenergetics such as 5′ Adenosine Monophosphate-Activated Protein Kinase (AMPK) and the phosphatidylinositol 3′-kinase (PI3K), protein kinase B (AKT), and the mammalian target of the rapamycin (mTOR) (PI3K/AKT/mTOR) signaling pathway should be mentioned as the attractive targets for novel anti-glioma drugs. This evidence concerns the gene AKT1 and central nervous system cancer.